BioSpace News Archive

The 3,400 registered nurses of Brigham and Women’s Hospital, represented by the Massachusetts Nurses Association, have decided to take public their concerns about how the hospital is hand

Hyasynth, a sustainable biotechnology company, takes top spot from global competitors by making the first ever sale of cannabidiol (CBD) produced and extracted from yeast.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the Chardan Virtual 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 p.m. ET. A live webcast of the presentation will be available on t

- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™ ), today announced that Sarah Boyce , President and Chief Executive Officer, Arthur Levin , Ph.D., Chief Scientific Officer, and Mike MacLean , Chi

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that Andrew Cheng , chief executive officer of Akero, will present virtually at the H.C

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 4 th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 4:15 pm ET via webcast. A live audio webcast of the presentation will be availa

Sapreme announced positive preclinical data on its proprietary endosomal escape platform in two presentations at the 16th Annual Meeting of the Oligonucleotide Therapeutics Society, held virtually from September 27th to 30th, 2020.

Precision BioSciences, Inc., a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies with its ARCUS® genome editing platform, announced its participation in the following upcoming virtual investor conferences:

INOVIO announced that the U.S. Food and Drug Administration has notified the company it has additional questions about the company’s planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA® 2000 delivery device to be used in the trial.

Enanta Pharmaceuticals, Inc. announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference on October 5, 2020 at 2:00 pm ET.